{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:59:12Z","timestamp":1791223152237,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This clinical trial sought to determine whether SL\u2010172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher\u2010risk myelodysplastic syndrome (HR\u2010MDS) or acute myeloid leukemia (AML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Dose escalation: doses of 1, 3, and 6 mg\/kg SL\u2010172154 was evaluated as monotherapy or in combination with AZA in patients with relapsed, refractory HR\u2010MDS or AML. Expansion: a SL\u2010172154 dose that could be safely combined with AZA was evaluated in patients with previously untreated HR\u2010MDS or\n                      <jats:italic>TP53<\/jats:italic>\n                      mutant (\n                      <jats:italic>TP53<\/jats:italic>\n                      m) AML. Objectives: safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty\u2010one patients with HR\u2010MDS (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a033) or AML (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a048) were enrolled in dose escalation (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a037) or expansion (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a044). Infusion\u2010related reaction was the most common SL\u2010172154\u2010related toxicity and led to a dose limiting toxicity at 6 mg\/kg. A dose of 3 mg\/kg SL\u2010172154 plus AZA was evaluated in patients with previously untreated HR\u2010MDS (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a021 with\n                      <jats:italic>TP53<\/jats:italic>\n                      m\u00a0and\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a03 with\n                      <jats:italic>TP53<\/jats:italic>\n                      wild type) and AML (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a021 with\n                      <jats:italic>TP53<\/jats:italic>\n                      m). CD47 and CD40 engagement by SL\u2010172154 was detected on leukemic blasts, myeloid, and lymphoid cells. Complete remission (CR) was achieved in 10 of 24 (43%) HR\u2010MDS and six of 21 (29%)\n                      <jats:italic>TP53<\/jats:italic>\n                      m AML patients with median overall survival (OS) of 11.0 months (95% CI, 5.0\u201315.6) and 11.7 months (95% CI, 1.97\u2013NE), respectively. Of patients in a CR, six of 10 HR\u2010MDS and three of six\n                      <jats:italic>TP53<\/jats:italic>\n                      m AML patients achieved complete cytogenetic CR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      SL\u2010172154 plus AZA was generally well tolerated with favorable CR rates in pts with\n                      <jats:italic>TP53<\/jats:italic>\n                      m HR\u2010MDS or AML, although without substantial improvement in OS when compared to historical benchmarks for AZA or AZA\/VEN, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70626","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:56:22Z","timestamp":1791125782000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc\u2010fusion protein SL\u2010172154 (SIRP\u03b1\u2010Fc\u2010CD40L) in patients with higher\u2010risk myelodysplastic syndrome or acute myeloid leukemia"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Yale School of Medicine and Yale Cancer Center Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Center  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Maher","sequence":"additional","affiliation":[{"name":"VCU Massey Cancer Center  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Curran","sequence":"additional","affiliation":[{"name":"University of Cincinnati  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Bixby","sequence":"additional","affiliation":[{"name":"University of Michigan Health Systems  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxing","family":"Chai\u2010Ho","sequence":"additional","affiliation":[{"name":"University of California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.\u00a0L.","family":"Yee","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute St. Mathew\u2019s  Louisville Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawa","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Medd","sequence":"additional","affiliation":[{"name":"Derriford Hospital Plymouth  Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-3081","authenticated-orcid":false,"given":"Emma","family":"Searle","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust and the University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sochacki","sequence":"additional","affiliation":[{"name":"START Midwest  Grand Rapids Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Savoie","sequence":"additional","affiliation":[{"name":"University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Green","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Kato","sequence":"additional","affiliation":[{"name":"Shattuck Labs  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Shattuck Labs  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Metenou","sequence":"additional","affiliation":[{"name":"Shattuck Labs  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[{"name":"Shattuck Labs  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9194-6348","authenticated-orcid":false,"given":"Lini","family":"Pandite","sequence":"additional","affiliation":[{"name":"Shattuck Labs  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor H.","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Shattuck Labs  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00333\u20102"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000617"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016229"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-235","article-title":"Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment\u2010na\u00efve, intermediate and higher\u2010risk myelodysplastic syndromes (HR MDS)","author":"Garcia\u2010Manero G","year":"2025","journal-title":"Blood"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006239"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010312"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432650"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005859"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201022\u20101183"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201022\u20100332"},{"key":"e_1_2_9_15_1","article-title":"Immune gene\u00a0expression profiling in children and adults with acute myeloid leukemia identifies distinct phenotypic patterns","volume":"130","author":"Vadakekolathu JPT","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002512"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916206117"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006158"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201002394"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.046"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222861110"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001375"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.07.016"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3931"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010020\u20102611\u20103"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1236332"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3311"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.10.13251"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20102355"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010022\u201001319\u20102"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010med\u2010062518\u2010045435"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.CIR\u201019\u20100493"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102024\u2010010565"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201003\u2010643544"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201003\u2010420489"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201010\u20104149"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010733196"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02604"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02342"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027408"},{"key":"e_1_2_9_46_1","unstructured":"NIH.APR\u2010246 & azacitidine for the treatment of TP53 mu\u2010tant myelodysplastic syndromes (MDS). NCT03745716.https:\/\/clinicaltrials.gov\/study\/NCT03745716?intr=Eprenetapopt%20(APR\u2010246)&viewType=Card&rank=9&tab=study"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027506"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1422864"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1759051"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002230\u2010w"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010020\u20101008\u2010z"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:46:42Z","timestamp":1791222402000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":51,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1002\/cncr.70626"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70626","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"2026-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70626"}}